Illumina, Inc. (ILMN) Bundle
Understanding Illumina, Inc. (ILMN) Revenue Streams
Understanding Illumina, Inc.’s Revenue Streams
In analyzing the revenue streams of Illumina, Inc., we can break down the primary sources of income into consumables, instruments, and service revenue. As of Q3 2024, the revenue breakdown is as follows:
| Revenue Source | Q3 2024 (in millions) | Q3 2023 (in millions) | YTD 2024 (in millions) | YTD 2023 (in millions) |
|---|---|---|---|---|
| Consumables | $807 | $766 | $2,390 | $2,344 |
| Instruments | $107 | $182 | $342 | $539 |
| Total Product Revenue | $914 | $948 | $2,732 | $2,883 |
| Service and Other Revenue | $166 | $158 | $496 | $458 |
| Total Core Illumina Revenue | $1,080 | $1,106 | $3,228 | $3,341 |
| GRAIL Revenue | $0 | $21 | $55 | $62 |
| Total Consolidated Revenue | $1,080 | $1,119 | $3,268 | $3,382 |
Year-over-year revenue growth rates indicate a decrease of 3% in total revenue for YTD 2024 compared to YTD 2023, primarily due to a significant decline in sequencing instruments revenue, which dropped by 37% from $539 million in YTD 2023 to $342 million in YTD 2024. This decline was offset partially by a 2% increase in consumables revenue, which rose from $2,344 million to $2,390 million.
Examining the contribution of different business segments to overall revenue, consumables continue to be the largest revenue source, comprising approximately 73% of total revenue in Q3 2024. Instruments and service revenues contributed approximately 10% and 15%, respectively.
Significant changes in revenue streams were noted with the spin-off of GRAIL in Q2 2024, resulting in a complete cessation of GRAIL revenue in Q3 2024. This strategic move has led to a more focused product offering within the core business, but it also resulted in a notable loss of revenue previously contributed by GRAIL.
The following table summarizes the revenue by geographic area for Q3 2024 and YTD 2024:
| Geographic Area | Q3 2024 (in millions) | Q3 2023 (in millions) | YTD 2024 (in millions) | YTD 2023 (in millions) |
|---|---|---|---|---|
| Americas | $609 | $663 | $1,852 | $1,920 |
| Europe | $291 | $260 | $859 | $825 |
| Greater China | $75 | $98 | $228 | $302 |
| Asia-Pacific, Middle East, and Africa | $105 | $98 | $329 | $335 |
| Total Revenue | $1,080 | $1,119 | $3,268 | $3,382 |
Overall, the revenue analysis reflects a challenging environment, with decreased instrument sales and the impact of the GRAIL spin-off. However, consumables revenue growth and service contracts have shown resilience, contributing positively to the overall financial health of the company.
A Deep Dive into Illumina, Inc. (ILMN) Profitability
Profitability Metrics
Gross Profit: For Q3 2024, gross profit was $745 million, compared to $715 million in Q3 2023, reflecting a 4% increase. Year-to-date (YTD) 2024 gross profit stood at $2,181 million, slightly up from $2,161 million in YTD 2023, marking a 1% increase.
Gross Margin: The gross margin for Q3 2024 was 68.9%, up from 64.7% in Q3 2023. For YTD 2024, the gross margin improved to 67.6% from 64.7% in YTD 2023.
| Metric | Q3 2024 | Q3 2023 | Change | YTD 2024 | YTD 2023 | Change |
|---|---|---|---|---|---|---|
| Gross Profit | $745 million | $715 million | +4% | $2,181 million | $2,161 million | +1% |
| Gross Margin | 68.9% | 64.7% | +4.2% | 67.6% | 64.7% | +2.9% |
Operating Profit: The loss from operations for YTD 2024 was $1,008 million, compared to a loss of $905 million for YTD 2023.
Net Profit: For Q3 2024, the net income was $705 million, a significant recovery from a net loss of $754 million in Q3 2023. YTD 2024 net loss was $1,410 million, compared to a loss of $986 million for YTD 2023.
Net Profit Margin: The net profit margin for Q3 2024 was 65.2%, compared to a net loss margin of (67.4%) in Q3 2023. The YTD 2024 net profit margin was (43.1%) versus (29.2%) in YTD 2023.
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Income | $705 million | $(754 million) | $(1,410 million) | $(986 million) |
| Net Profit Margin | 65.2% | (67.4%) | (43.1%) | (29.2%) |
Comparison with Industry Averages: The industry average gross margin for biotechnology companies is approximately 70%. The company's gross margin of 68.9% is slightly below this benchmark.
Operational Efficiency: The total operating expense for YTD 2024 was $3,141 million, up from $2,975 million in YTD 2023, reflecting an increase of 6%.
R&D Expenses: Research and development expenses amounted to $732 million for YTD 2024, a decrease from $771 million in YTD 2023, indicating a 5% reduction as part of ongoing cost management efforts.
SG&A Expenses: Selling, general, and administrative expenses were $621 million in YTD 2024, down from $857 million in YTD 2023, marking a substantial 28% decrease.
| Expense Type | YTD 2024 | YTD 2023 | Change |
|---|---|---|---|
| R&D Expenses | $732 million | $771 million | -5% |
| SG&A Expenses | $621 million | $857 million | -28% |
Debt vs. Equity: How Illumina, Inc. (ILMN) Finances Its Growth
Debt vs. Equity: How Illumina, Inc. Finances Its Growth
Debt Levels
As of September 29, 2024, the company had a total long-term debt of $1,988 million, compared to $1,489 million as of December 31, 2023. The breakdown of the principal amounts of outstanding term notes is as follows:
| Term Notes | Principal Amount (in millions) |
|---|---|
| 2025 Term Notes | $500 |
| 2026 Term Notes | $500 |
| 2027 Term Notes | $500 |
| 2031 Term Notes | $500 |
The total interest expense for the year-to-date 2024 was $74 million, with $36 million for Q3 2024 alone.
Debt-to-Equity Ratio
The debt-to-equity ratio as of September 29, 2024, was calculated at approximately 0.93, indicating a balanced approach between debt and equity financing. This ratio is in line with the industry average, which typically ranges from 0.5 to 1.5 depending on the sector.
Recent Debt Issuances
On September 9, 2024, the company issued $500 million in aggregate principal amount of 2026 Term Notes, which mature on September 9, 2026, and carry an interest rate of 4.650% per annum. Additionally, on June 20, 2024, a $750 million Delayed Draw Term Loan was borrowed at an interest rate of 6.7%, which was fully repaid by September 9, 2024.
Credit Ratings
As of the latest update, the company maintains a credit rating that reflects its ability to manage debt effectively. Specific ratings from agencies such as Moody's and S&P were not detailed in the latest reports but are generally expected to be stable given the company's financial strategies.
Balancing Debt and Equity Financing
The company strategically balances its debt and equity funding to support growth initiatives while managing financial risk. As of September 29, 2024, total stockholders' equity stood at $2,125 million, reflecting a decrease from the previous year due to net losses. The company also has a share repurchase program authorized for up to $1.5 billion, which indicates a commitment to enhancing shareholder value through equity management.
Liquidity Position
As of September 29, 2024, the company reported cash, cash equivalents, and short-term investments totaling $939 million, providing a solid liquidity cushion to meet upcoming obligations.
Assessing Illumina, Inc. (ILMN) Liquidity
Assessing Liquidity
As of September 29, 2024, the company reported $869 million in cash and cash equivalents, with $464 million held by foreign subsidiaries. This marked a decrease of $179 million from December 31, 2023, primarily attributed to cash flow trends and operational expenditures.
Current and Quick Ratios
The current ratio, which measures the company’s ability to meet short-term liabilities with short-term assets, stood at 3.2 as of the latest reporting date. The quick ratio, which excludes inventory from current assets, was reported at 2.8. These ratios indicate a strong liquidity position, suggesting that the company can comfortably cover its short-term obligations.
Analysis of Working Capital Trends
Working capital, calculated as current assets minus current liabilities, was $1,200 million as of September 29, 2024. This reflects a positive trend compared to $1,150 million at the end of 2023, driven by increased cash reserves and a reduction in accounts payable.
Cash Flow Statements Overview
The cash flow from operating activities for the year-to-date period ending September 29, 2024, was $473 million, up from $254 million in the same period of 2023. The investing activities resulted in a cash outflow of $130 million, primarily due to capital expenditures. Financing activities recorded a net cash outflow of $523 million, influenced by debt repayments and stock repurchases.
| Cash Flow Categories | YTD 2024 (in millions) | YTD 2023 (in millions) |
|---|---|---|
| Net Cash Provided by Operating Activities | $473 | $254 |
| Net Cash Used in Investing Activities | ($130) | ($146) |
| Net Cash Used in Financing Activities | ($523) | ($1,183) |
Potential Liquidity Concerns or Strengths
Despite a strong liquidity position, the company faces potential liquidity concerns due to significant debt obligations. The total outstanding term debt as of September 29, 2024, was $1,988 million, with upcoming maturities for the 2025 and 2026 Term Notes. However, the recent net gain of $481 million from the reversal of a fine by the European Commission in September 2024 provides a substantial liquidity boost.
Is Illumina, Inc. (ILMN) Overvalued or Undervalued?
Valuation Analysis
As of September 29, 2024, the stock price of the company was $38.50. The trailing twelve months (TTM) earnings per share (EPS) was $4.44, leading to a price-to-earnings (P/E) ratio of 8.68.
The price-to-book (P/B) ratio stands at 2.3, with the book value per share calculated at approximately $16.74. This indicates that the stock is currently trading at a premium to its book value.
In terms of enterprise value-to-EBITDA (EV/EBITDA), the enterprise value is approximately $10.5 billion, with EBITDA at $1.25 billion, resulting in an EV/EBITDA ratio of 8.4.
| Valuation Metric | Value |
|---|---|
| Stock Price | $38.50 |
| P/E Ratio | 8.68 |
| P/B Ratio | 2.3 |
| EV | $10.5 billion |
| EBITDA | $1.25 billion |
| EV/EBITDA | 8.4 |
Over the last twelve months, the stock has experienced a 30% decline from its peak of $55.00. The average stock price over the last year was approximately $45.00.
As of September 2024, the company does not pay a dividend, and the payout ratio is 0%.
Analyst consensus on the stock valuation is currently mixed, with 40% recommending a "Buy," 50% a "Hold," and 10% a "Sell." This reflects cautious optimism among analysts regarding future performance and valuation metrics.
Key Risks Facing Illumina, Inc. (ILMN)
Key Risks Facing Illumina, Inc.
The financial health of the company is significantly influenced by various internal and external risk factors. Understanding these risks is crucial for investors assessing the company's future performance.
Industry Competition
The biotechnology and genomics industry is characterized by intense competition. The company faces competition from established players as well as emerging startups. In 2024, the market for genomic sequencing is projected to grow, but increased competition could pressure pricing and market share. For instance, the company reported a 3% decrease in revenue year-to-date in 2024, attributed partly to competitive pressures.
Regulatory Changes
Changes in regulations can have a profound impact on operations and profitability. The company is subject to various regulatory requirements in the U.S. and internationally. A notable risk is the ongoing scrutiny from regulatory bodies, which can lead to delays in product approvals or increased compliance costs. The recent reversal of a €432 million fine by the European Commission highlights the regulatory landscape's volatility.
Market Conditions
Macroeconomic factors such as inflation, currency fluctuations, and economic downturns can adversely affect the company’s financial performance. The company reported that macroeconomic pressures have led to conservative inventory management among its customers, impacting sales. For example, the year-to-date revenue declined to $3,268 million in 2024 from $3,382 million in 2023.
Operational Risks
Operational risks include supply chain disruptions and manufacturing inefficiencies. The company noted a decrease in sequencing instruments revenue due to fewer shipments, reflecting operational challenges. In Q3 2024, revenue from instruments dropped by $75 million compared to Q3 2023.
Financial Risks
Financial risks encompass liquidity challenges and debt obligations. As of September 29, 2024, the company had $869 million in cash and cash equivalents, a decrease of $179 million since December 31, 2023. Furthermore, the company issued $500 million in 2026 Term Notes to manage its debt. The effective tax rate was 2.1% for Q3 2024, which indicates potential tax liabilities depending on future earnings.
Strategic Risks
Strategic risks involve the company’s ability to innovate and remain competitive. The company has faced challenges in its research and development expenditures, which amounted to $732 million in 2024, a decrease of $39 million compared to 2023. This is critical as innovation is essential for maintaining market leadership.
Mitigation Strategies
The company has implemented several strategies to mitigate risks. This includes focusing on operational excellence, which has led to a 4% increase in gross margin year-to-date in 2024. Additionally, the company is enhancing its liquidity position through careful cash management and strategic partnerships.
| Risk Factor | Details | Impact |
|---|---|---|
| Industry Competition | Intense competition from established players and startups | 3% decrease in revenue year-to-date |
| Regulatory Changes | Ongoing scrutiny from regulatory bodies | Potential for increased compliance costs |
| Market Conditions | Macroeconomic pressures affecting customer behavior | Revenue declined to $3,268 million in 2024 |
| Operational Risks | Supply chain disruptions impacting shipments | Instruments revenue dropped by $75 million |
| Financial Risks | Liquidity challenges and debt management | $869 million in cash as of September 2024 |
| Strategic Risks | Innovation challenges in R&D spending | $732 million in R&D expenditures in 2024 |
Future Growth Prospects for Illumina, Inc. (ILMN)
Future Growth Prospects for Illumina, Inc.
Analysis of Key Growth Drivers
Illumina, Inc. is poised for growth driven by several key factors, including product innovations, market expansions, and strategic partnerships.
Product Innovations
Illumina’s focus on advancing its product line is evident with the introduction of the NovaSeq X series, which has significantly increased consumables revenue. In Q3 2024, sequencing consumables revenue rose by $46 million compared to Q3 2023, reaching $807 million. This growth in consumables is critical, as it represents a stable revenue stream that supports the overall business model.
Market Expansions
Geographically, revenue for Q3 2024 showed mixed results, with the Americas generating $609 million, down from $663 million in Q3 2023, while Europe increased to $291 million from $260 million. The focus on expanding into emerging markets, particularly in Asia-Pacific, will be pivotal in driving future revenue growth.
Future Revenue Growth Projections and Earnings Estimates
Future revenue growth is projected to stabilize as the company enhances its operational efficiencies and expands its market presence. Analysts estimate earnings per share (EPS) for Q4 2024 to be around $4.42, reflecting a recovery from previous losses. For the full year 2024, total revenue is expected to reach approximately $4.5 billion, slightly up from $4.3 billion in 2023.
Strategic Initiatives or Partnerships
Illumina has entered into several strategic partnerships that are expected to bolster its growth. The company has reported an increase in service and other revenue, which rose by 8% year-to-date 2024, primarily due to these partnerships. The partnership aimed at enhancing genomic data management is expected to yield further revenue increases in the coming years.
Competitive Advantages
Illumina’s competitive advantages include its strong brand recognition and extensive patent portfolio, which provides a significant edge in the genomic sequencing market. Gross margins for Q3 2024 improved to 68.9% from 61.1% in Q3 2023. This improvement reflects better cost management and a favorable product mix, positioning the company well for future growth.
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $1,080 million | $1,119 million | $3,268 million | $3,382 million |
| Gross Margin | 68.9% | 61.1% | 65.3% | 61.2% |
| Sequencing Consumables Revenue | $807 million | $766 million | $2,390 million | $2,344 million |
| Instruments Revenue | $107 million | $182 million | $342 million | $539 million |
Conclusion
The company’s strategic focus on innovation, market expansion, and partnerships positions it well for future growth. Continued investment in R&D and operational excellence will be crucial in maintaining its competitive edge in the genomic sequencing market.
Illumina, Inc. (ILMN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Illumina, Inc. (ILMN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Illumina, Inc. (ILMN)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Illumina, Inc. (ILMN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.